ArticleScientific reports2025
Evaluation of Chlamydia pecorum major outer membrane protein vaccine a management tool in wild koala (Phascolarctos cinereus) populations.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chlamydiosis is a significant disease affecting Eastern Australian koalas (Phascolarctos cinereus), contributing to the decline of some koala populations, necessitating investigations into appropriate management strategies to address chlamydiosis in wild koala populations. The aim of this study was to investigate the effect of a Chlamydia pecorum recombinant Major Outer Membrane Protein (rMOMP) vaccine as a potential strategy for managing chlamydiosis at a population level. This study comprised a blinded, randomised placebo-controlled trial, encompassing different koala populations where chlamydiosis is having differing effects. Wild koalas were recruited into a vaccination or a placebo treatment group and followed for 12 months, with recapture and resampling at 2, 6 and 12 months post vaccination. Vaccination stimulated a significant plasma anti-MOMP IgG response and greater IL-17 and TNFα mRNA fold change from rMOMP stimulated leukocytes, however, did not boost pre-existing immune responses, from natural infection, in koalas. The observed immunological stimulation did not translate to any effect on chlamydiosis or chlamydial shedding in our study populations. These findings highlight the necessity of improving our understanding of what constitutes a protective immune response in koalas to guide the development of a more effective vaccine. This study evaluated the estimated effect of vaccination necessary to achieve management outcomes predicted by modelling studies. It is possible that vaccination has a more modest effect and could benefit koala populations with a lower disease prevalence or be useful in conjunction with additional management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.